MOMETASONE FUROATE | N019543 | ORGANON LLC A SUB OF ORGANON AND CO
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | Sanofi | 216 | 2025-02-06 → 2027-02-17 | |
| Phase 3 | Active | Sanofi | 231 | 2025-02-12 → 2027-03-26 | |
| Phase 2 | By Invitation | Sanofi | 71 | 2025-05-12 → 2031-01-29 | |
| N/A | Not Yet Recruiting | Liaquat University of Medical & Health Sciences | 78 | 2026-09-14 → 2027-05-31 | |
| N/A | Not Yet Recruiting | Liaquat University of Medical & Health Sciences | 64 | 2026-09-07 → 2027-07-30 | |
| N/A | Not Yet Recruiting | Zhongshan Torch Development Zone People's Hospital | 150 | 2026-08-31 → 2027-01-20 | |
| N/A | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 50 | 2024-05-24 → 2026-12 | |
| Phase 4 | Completed | Organon and Co | 401 | 2006-05 → 2006-11 | |
| Phase 3 | Completed | GlaxoSmithKline | 414 | 2017-05-25 → 2019-12-11 | |
| Phase 2 | Completed | Sanofi | 60 | 2013-08 → 2014-11 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
20 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jul 7, 2026 | SUPPL -29 | View Letter (PDF) |
| May 24, 2018 | SUPPL -28 | View Letter (PDF) |
| Apr 1, 2013 | SUPPL -24 | View Letter (PDF) |
| Jun 3, 2004 | SUPPL -14 | View Letter (PDF) |
| Jul 17, 2002 | SUPPL -13 | View Letter (PDF) |
| Jul 17, 2002 | SUPPL -11 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.